TheStreet Downgrades Tabula Rasa HealthCare (NASDAQ:TRHC) to D+

Tabula Rasa HealthCare (NASDAQ:TRHC) was downgraded by stock analysts at TheStreet from a “c-” rating to a “d+” rating in a research report issued to clients and investors on Tuesday, TheStreetRatingsTable reports.

Several other equities analysts have also issued reports on the company. Zacks Investment Research raised Tabula Rasa HealthCare from a “sell” rating to a “hold” rating in a report on Saturday, June 8th. ValuEngine lowered Tabula Rasa HealthCare from a “buy” rating to a “hold” rating in a report on Monday, May 13th. Cantor Fitzgerald reaffirmed a “buy” rating and set a $99.00 price objective on shares of Tabula Rasa HealthCare in a report on Monday, May 13th. Piper Jaffray Companies raised their price target on Tabula Rasa HealthCare from $73.00 to $78.00 and gave the stock an “overweight” rating in a report on Thursday, May 9th. Finally, BidaskClub raised Tabula Rasa HealthCare from a “sell” rating to a “hold” rating in a report on Tuesday, May 7th. Five analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $82.12.

Shares of TRHC stock opened at $48.52 on Tuesday. The stock has a market cap of $997.17 million, a price-to-earnings ratio of 142.71 and a beta of 1.69. Tabula Rasa HealthCare has a 1 year low of $40.86 and a 1 year high of $91.16. The company has a debt-to-equity ratio of 1.31, a quick ratio of 1.73 and a current ratio of 1.80.

Tabula Rasa HealthCare (NASDAQ:TRHC) last issued its quarterly earnings data on Wednesday, May 8th. The company reported ($0.14) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.14). The company had revenue of $60.96 million for the quarter, compared to analyst estimates of $59.24 million. Tabula Rasa HealthCare had a positive return on equity of 4.22% and a negative net margin of 18.15%. Analysts predict that Tabula Rasa HealthCare will post -0.55 earnings per share for the current year.

In other Tabula Rasa HealthCare news, CEO Calvin H. Knowlton sold 8,000 shares of Tabula Rasa HealthCare stock in a transaction that occurred on Friday, June 7th. The stock was sold at an average price of $44.08, for a total value of $352,640.00. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Calvin H. Knowlton sold 8,270 shares of Tabula Rasa HealthCare stock in a transaction that occurred on Tuesday, May 7th. The shares were sold at an average price of $53.68, for a total value of $443,933.60. The disclosure for this sale can be found here. In the last three months, insiders have sold 48,270 shares of company stock worth $2,462,254. Corporate insiders own 14.00% of the company’s stock.

A number of institutional investors and hedge funds have recently made changes to their positions in TRHC. First Mercantile Trust Co. acquired a new stake in shares of Tabula Rasa HealthCare during the 4th quarter valued at approximately $39,000. Neuburgh Advisers LLC lifted its position in shares of Tabula Rasa HealthCare by 34.9% during the 1st quarter. Neuburgh Advisers LLC now owns 2,288 shares of the company’s stock valued at $129,000 after acquiring an additional 592 shares during the period. Oppenheimer Asset Management Inc. acquired a new stake in shares of Tabula Rasa HealthCare during the 4th quarter valued at approximately $135,000. South Dakota Investment Council acquired a new stake in shares of Tabula Rasa HealthCare during the 1st quarter valued at approximately $141,000. Finally, Belpointe Asset Management LLC acquired a new stake in shares of Tabula Rasa HealthCare during the 1st quarter valued at approximately $172,000. 86.66% of the stock is currently owned by institutional investors.

About Tabula Rasa HealthCare

Tabula Rasa HealthCare, Inc operates as a healthcare technology company in the field of medication safety in the United States. The company's proprietary Medication Risk Mitigation Matrix delivers a multi-drug review, which identifies medication-related risks. Its cloud-based software applications include EireneRx, a medication decision-support and e-prescribing platform to access patients' medication-related information; and MedWise that provides medication decision support components for clients seeking to manage their medication risk and improve medication outcomes, and patient relationships by enhancing their existing systems.

Further Reading: Special Dividends

Analyst Recommendations for Tabula Rasa HealthCare (NASDAQ:TRHC)

Receive News & Ratings for Tabula Rasa HealthCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tabula Rasa HealthCare and related companies with MarketBeat.com's FREE daily email newsletter.